Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher cost - Bloomberg
Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...
The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering ... on the CRISPR/Cas9 gene-editing technology to be approved towards the end of last year, when it was ...
2don MSN
Here's why four Motley Fool contributors think chip giants Nvidia ( NVDA -0.26%) and Micron Technologies ( MU -1.05%), travel services company Airbnb ( ABNB -0.83%), biotech behemoth Vertex ...
Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
The first-ever CRISPR-based gene-editing therapy has been approved for marketing in the ... products Regulatory Agency (MHRA) cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback